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Introduction {#jdv15277-sec-0006}
============

Psoriasis is a common inflammatory skin condition, estimated to affect 2--3% of the worldwide population.[1](#jdv15277-bib-0001){ref-type="ref"} Moderate‐to‐severe chronic plaque psoriasis symptoms have a significant negative impact on patient quality of life[2](#jdv15277-bib-0002){ref-type="ref"} and are associated with a considerable economic burden.[3](#jdv15277-bib-0003){ref-type="ref"} Approximately 90% of cases require long‐term therapy[4](#jdv15277-bib-0004){ref-type="ref"}; therefore, therapies with favourable efficacy and safety as demonstrated in longer‐term trials stand to make a meaningful difference to the lives of patients.[5](#jdv15277-bib-0005){ref-type="ref"}

Treatments such as the anti‐tumour necrosis factor (TNF) therapies, adalimumab, etanercept and infliximab, and the interleukin (IL)‐12/23 inhibitor, ustekinumab, transformed the treatment of psoriasis when they were approved. More recently, three therapies focusing on the IL‐17 pathway have been approved: secukinumab and ixekizumab, both IL‐17A inhibitors, and brodalumab, a human monoclonal antibody which targets the IL‐17 receptor A (IL‐17RA) on keratinocytes and immune cells. These biological therapies, along with the phosphodiesterase 4 (PD4) inhibitor apremilast, have proven to be effective options for many patients, though they are typically available only to patients with moderate‐to‐severe disease who have failed or are ineligible for conventional systemic therapy.

Despite their importance, comparisons of long‐term outcomes in patients with psoriasis are limited due to complicated trial designs and inconsistencies in analysis and data handling methods used.[6](#jdv15277-bib-0006){ref-type="ref"} Many long‐term trials have multiple phases, are not clear or consistent in how they deal with imputations of missing observations or even in which population outcomes are being analysed. For these reasons, most systematic literature reviews (SLRs) and meta‐analyses in psoriasis have focused on induction phase outcomes. One 2015 review and meta‐analysis compared 24‐week outcomes of standard systemic and biological therapies,[7](#jdv15277-bib-0007){ref-type="ref"} though the authors also noted limitations of the long‐term data available. Since then, several 52‐week randomized controlled trials (RCTs) have been published demonstrating the longer‐term efficacy of some licensed therapies. To our knowledge, no formal synthesis of these outcomes has been attempted.

With so many therapies licensed for moderate‐to‐severe psoriasis and only a few compared directly in a head‐to‐head fashion, traditional pairwise meta‐analysis alone is insufficient to guide practical clinical decision making. Network meta‐analysis (NMA) offers a set of methods to visualize and interpret a broad evidence base and to determine the comparative efficacy of multiple interventions.[8](#jdv15277-bib-0008){ref-type="ref"} The technique borrows strength from indirect evidence to enable the simultaneous evaluation of relative effects that have not been investigated directly in RCTs[9](#jdv15277-bib-0009){ref-type="ref"} and has been used extensively to evaluate short‐term effects of psoriasis treatments.[10](#jdv15277-bib-0010){ref-type="ref"}, [11](#jdv15277-bib-0011){ref-type="ref"}, [12](#jdv15277-bib-0012){ref-type="ref"}, [13](#jdv15277-bib-0013){ref-type="ref"}, [14](#jdv15277-bib-0014){ref-type="ref"}, [15](#jdv15277-bib-0015){ref-type="ref"}, [16](#jdv15277-bib-0016){ref-type="ref"}, [17](#jdv15277-bib-0017){ref-type="ref"}, [18](#jdv15277-bib-0018){ref-type="ref"}, [19](#jdv15277-bib-0019){ref-type="ref"}, [20](#jdv15277-bib-0020){ref-type="ref"}, [21](#jdv15277-bib-0021){ref-type="ref"}, [22](#jdv15277-bib-0022){ref-type="ref"}, [23](#jdv15277-bib-0023){ref-type="ref"}, [24](#jdv15277-bib-0024){ref-type="ref"}

The objective of this study was to compare novel systemic therapies, both biologic and non‐biologic, approved for the treatment of moderate‐to‐severe psoriasis by conducting a SLR and NMA of Psoriasis Area and Severity Index (PASI) outcomes measured at or around 1 year.

Materials and methods {#jdv15277-sec-0007}
=====================

Systematic literature review {#jdv15277-sec-0008}
----------------------------

An SLR was performed to identify RCT evidence that assessed the efficacy of biologic therapies and apremilast in adult patients with moderate‐to‐severe chronic plaque psoriasis. PRISMA (Preferred Reporting Items for Systematic reviews and Meta‐Analyses and network meta‐analyses) reporting guidelines were followed throughout.[25](#jdv15277-bib-0025){ref-type="ref"}, [26](#jdv15277-bib-0026){ref-type="ref"}

MEDLINE, Embase and Cochrane Library databases were searched for articles published in English from 2000 to 31 August 2016 (Table [S1](#jdv15277-sup-0001){ref-type="supplementary-material"}). Search strings combined terms related to psoriasis, to specific therapies and to RCTs. Screening of potentially relevant publications was performed double‐blind, with a third reviewer resolving any differences as to eligibility. Supplementary searching included a bibliography review, congress abstract searching and hand searching. Bibliographies of included studies were cross‐referenced with the search results to identify additional studies. Abstracts of relevant disease‐specific and health economics and outcomes research congresses from 2013 to 31 August 2016 were searched. Finally, a hand search was performed in February 2017 to identify additional full‐text publications reporting on trials that had been included as abstracts in the original SLR.

Only RCTs comparing an intervention of interest -- adalimumab, apremilast, brodalumab, etanercept, infliximab, ixekizumab, secukinumab and ustekinumab -- with any comparator, including placebo and unlicensed doses of biological and non‐biological systemic therapies, were included in the systematic review. The NMA included only doses of biological therapies and apremilast licensed by the European Medicines Agency (EMA). The main outcome of interest was the proportion of patients achieving 75%, 90% and 100% improvements in PASI score at between 40‐ and 64‐week follow‐up (PASI 75, PASI 90 and PASI 100).

For each study meeting the inclusion criteria, study design details, patient demographics, therapy details, efficacy endpoints and statistical analyses were extracted, with particular attention paid to patient follow‐up and the handling of missing data. The methodological quality of included studies was assessed using the Cochrane Risk of Bias Tool.[27](#jdv15277-bib-0027){ref-type="ref"} Potential risk of bias was determined by assessing heterogeneity of treatment and outcome characteristics as well as study and patient characteristics.

Analysis {#jdv15277-sec-0009}
--------

To determine the feasibility and appropriateness of analysis, included studies were compared to assess heterogeneity in terms of treatment and outcome characteristics as well as study and patient characteristics. The planning and execution of all analyses adhered to internationally recommended methods.[28](#jdv15277-bib-0028){ref-type="ref"}, [29](#jdv15277-bib-0029){ref-type="ref"} Relevant study results were combined by means of a hierarchical Bayesian NMA of PASI responses using an ordered probit model to estimate probabilities of achieving different levels of response (e.g. PASI 75, PASI 90 and PASI 100). This is the preferred model when synthesizing ordered categorical data as it makes efficient use of all available trial data, even where different trials use different thresholds or report different numbers of thresholds, by assuming that the treatment effect is the same regardless of response level.[29](#jdv15277-bib-0029){ref-type="ref"}, [30](#jdv15277-bib-0030){ref-type="ref"} Prior exposure to biological therapies varies across trials of psoriasis and is thought to be an potential effect modifier; therefore, a sensitivity analysis was run excluding studies which do not report or in which \<5% of patients report prior experience with biologics.

Results were generated using both fixed‐ and random‐effects models, and compared for goodness of fit to the data, calculated as the overall mean residual deviance. The model with the lowest deviance information criterion (DIC) was considered to have the 'best' fit to the data.[29](#jdv15277-bib-0029){ref-type="ref"} Inconsistency between direct and indirect estimates of effect was assessed for any loops in the evidence network using the two‐stage Bucher method.[30](#jdv15277-bib-0030){ref-type="ref"}, [31](#jdv15277-bib-0031){ref-type="ref"}

All analyses were performed using WinBUGS version 1.4 statistical software with non‐informative priors. An initial burn‐in of at least 20 000 simulations was used, and convergence was confirmed through visual inspection the Brook--Gelman--Rubin diagnostic and history plots. This was followed by 50 000 simulations on three chains to estimate the sampled parameters. Results are calculated as risk ratios (RRs) for each treatment compared to one another. Point estimates of the median value are presented, along with 95% credible intervals (95% CrI) reflecting the range of true effects with 95% probability. A numerical summary of each treatment\'s rank distribution, called the surface under the cumulative ranking (SUCRA) curve, is also presented.

Results {#jdv15277-sec-0010}
=======

Literature search results {#jdv15277-sec-0011}
-------------------------

Electronic searches identified 3441 publications, to which supplementary searching added a total of 31 additional references. After deduplication, 2997 titles and abstracts were screened, and full‐text versions of 225 publications were assessed. In total, 98 publications, covering 67 RCTs, were included (Fig. [1](#jdv15277-fig-0001){ref-type="fig"}).

![PRISMA flow diagram of SLR.](JDV-33-355-g001){#jdv15277-fig-0001}

Evidence network {#jdv15277-sec-0012}
----------------

Of the 98 publications identified in the SLR, 62 publications describing 54 RCTs reported PASI outcomes for a licensed dose of biologic therapy or apremilast at the end of a 10‐ to 16‐week induction period. Twenty‐four of these RCTs also reported on PASI outcomes measured at 40--64 weeks of follow‐up, but placebo‐ and active‐controlled data were limited. Most control arms did not continue beyond the short‐term induction period, yet controlled data are necessary to calculate comparative effect estimates.

Five studies were long‐term RCTs for which maintenance phase data were available for at least two trial arms. Fourteen studies were RCTs with a short‐term induction phase followed by an observational maintenance phase in which patients originally randomized to placebo crossed over to active therapy. Five studies were short‐term RCTs with a crossover maintenance phase followed by a rerandomized withdrawal‐controlled phase among treatment responders. From this heterogeneous data set of longer‐term outcomes, several analyses were planned and implemented (Fig. [2](#jdv15277-fig-0002){ref-type="fig"}).

![Study selection for network meta‐analysis (NMA).](JDV-33-355-g002){#jdv15277-fig-0002}

Analysis 1: NMA of 52‐week active therapy RCTs {#jdv15277-sec-0013}
----------------------------------------------

The primary analysis utilized data from four of the active‐controlled 52‐week RCTs[32](#jdv15277-bib-0032){ref-type="ref"}, [33](#jdv15277-bib-0033){ref-type="ref"}, [34](#jdv15277-bib-0034){ref-type="ref"} evaluating brodalumab, ustekinumab (weight‐based dosing: 45 mg if \<100 kg; 90 mg if \>100 kg), secukinumab and etanercept (50 mg BIW). The fifth study, PIECE,[35](#jdv15277-bib-0035){ref-type="ref"} was excluded due to its small sample size (*n* = 19) and the risk for Type II error.

Analysis 2: NMA of 52‐week RCTs using induction phase placebo control {#jdv15277-sec-0014}
---------------------------------------------------------------------

Building on the primary network, a secondary analysis was undertaken using evidence from 13 of the 14 crossover maintenance phase trials. The PHOENIX 2 trial was excluded due to outcomes being insufficiently reported for use in the analysis.[36](#jdv15277-bib-0036){ref-type="ref"}, [37](#jdv15277-bib-0037){ref-type="ref"} By design, these maintenance phases are like single‐arm studies, and thus data are non‐comparative. To use these data in the NMA, maintenance phase responses from licensed active therapy arms were compared to induction phase outcomes from placebo arms. This assumes that if patients randomized to placebo at the start of the trial had continued receiving placebo, there would have been no change in their likelihood or level of response. Making this assumption allowed for the inclusion of data for adalimumab, apremilast, infliximab and ixekizumab, as well as additional data for etanercept, secukinumab and ustekinumab (45 and 90 mg). Only data for patients starting on the licensed induction dose followed by the licensed maintenance dose were used. Maintenance phase data relating to patients who crossed over from unlicensed induction doses were excluded.

Data from the five studies with a withdrawal‐controlled phase were not included in the secondary analysis.[38](#jdv15277-bib-0038){ref-type="ref"}, [39](#jdv15277-bib-0039){ref-type="ref"}, [40](#jdv15277-bib-0040){ref-type="ref"}, [41](#jdv15277-bib-0041){ref-type="ref"} The responder‐enrichment design of these studies, that is the restriction of rerandomization only to patients who reached a predefined level of response, may bias results in favour of the active intervention.

A description of the 22 RCTs included in the primary and secondary analyses is provided in Table [1](#jdv15277-tbl-0001){ref-type="table"}, and an evidence network for both analyses is provided in Fig. [3](#jdv15277-fig-0003){ref-type="fig"}. A total of 2244 patients were included in the four 52‐week RCTs. A total of 6113 patients were included in the 17 trials forming the augmented network for PASI response. In the sensitivity analysis around prior biologic exposure, six studies[42](#jdv15277-bib-0042){ref-type="ref"}, [43](#jdv15277-bib-0043){ref-type="ref"}, [44](#jdv15277-bib-0044){ref-type="ref"}, [45](#jdv15277-bib-0045){ref-type="ref"}, [46](#jdv15277-bib-0046){ref-type="ref"}, [47](#jdv15277-bib-0047){ref-type="ref"} were excluded from the augmented network. Study‐level outcomes are reported in Table [S2](#jdv15277-sup-0001){ref-type="supplementary-material"}. Direct and indirect treatment effects were compared in the loops of evidence observed in the augmented network (Analysis 2), but no significant inconsistency was identified.

###### 

Baseline characteristics of studies included in primary and secondary analyses

  Study                                                                                                                                 Treatment            Sample size   Age (years)   Male     Weight (kg)   PsA    Disease duration (years)   Previous therapies   Percentage psoriasis‐affected BSA   PASI score   DLQI score                                                         
  ------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------- ------------- -------- ------------- ------ -------------------------- -------------------- ----------------------------------- ------------ ------------ ---- ---- ---- ------- ------- ------- ------- ------ -----
  AMAGINE‐2[a](#jdv15277-note-0003){ref-type="fn"} ^,^ [34](#jdv15277-bib-0034){ref-type="ref"}                                         Brodalumab 210 mg    612           334           45       13            69     91.0                       23.0                 19                                  19.0         12.0         52   77   29   26      16      20.3    8.3     14.7   7.1
  Ustekinumab (WBD)                                                                                                                     300                  289           45            13       68            91.0   24.0                       17                   19.0                                13.0         50           75   28   27   19      20.0    8.4     15.1    7.2    
  AMAGINE‐3[a](#jdv15277-note-0003){ref-type="fn"} ^,^ [34](#jdv15277-bib-0034){ref-type="ref"}                                         Brodalumab 210 mg    624           342           45       13            69     90.0                       23.0                 20                                  18.0         12.0         40   68   25   28      18      20.4    8.3     14.5   7.2
  Ustekinumab (WBD)                                                                                                                     313                  301           45            13       68            90.0   22.0                       20                   18.0                                12.0         44           70   24   28           20.1    8.4     14.6    7.4    
  CLEAR[a](#jdv15277-note-0003){ref-type="fn"} ^,^ [32](#jdv15277-bib-0032){ref-type="ref"}, [63](#jdv15277-bib-0063){ref-type="ref"}   Secukinumab 300 mg   337           337           45.2     14.0          68     87.4                       20.0                 21                                  19.6         12.9              65   14   33      18      21.7    8.5            
  Ustekinumab (WBD)                                                                                                                     339                  339           44.6          13.7     74            87.2   22.1                       16                   16.1                                11.2                      66   13   32   17      21.5    8.1                    
  FIXTURE[a](#jdv15277-note-0003){ref-type="fn"} ^,^ [33](#jdv15277-bib-0033){ref-type="ref"}                                           Secukinumab 300 mg   327           312           44.5     13.2          68     83.0                       21.6                 15                                  15.8         12.3              60   12   34      19      23.9    9.9     13.3   
  Etanercept 50 mg BIW                                                                                                                  326                  305           43.8          13.0     71            84.6   20.5                       14                   16.4                                12.0                      63   14   34   18      23.2    9.8     13.4           
  PHOENIX 1[64](#jdv15277-bib-0064){ref-type="ref"}                                                                                     Placebo              255                         44.8     11.3          72     94.2                       23.5                 35                                  20.4         11.7         59   56   50   28      17      20.4    8.6     11.8   7.4
  Ustekinumab 45 mg                                                                                                                     255                  251           44.8          12.5     69            93.7   23.8                       29                   19.7                                11.7         68           55   53   27   18      20.5    8.6     11.1    7.1    
  Ustekinumab 90 mg                                                                                                                     255                  246           46.2          11.3     68            93.8   23.9                       37                   19.6                                11.1         67           55   51   25   15      19.7    7.6     11.6    6.9    
  Igarashi 2012[43](#jdv15277-bib-0043){ref-type="ref"}                                                                                 Placebo              32                          49.0                   84     71.2                       10.9                 3                                   16.0         11.2         63   66   0    50      23      30.3    11.8    10.5   6.2
  Ustekinumab 45 mg                                                                                                                     64                   64            45.0                   83            73.2   15.4                       9                    15.8                                8.2          56           73   2    47   24      30.1    12.9    11.4    6.5    
  Ustekinumab 90 mg                                                                                                                     62                   58            44.0                   76            71.1   14.0                       11                   17.3                                10.7         82           84   0    47   20      28.7    11.2    10.7    6.4    
  JUNCTURE[65](#jdv15277-bib-0065){ref-type="ref"}, [66](#jdv15277-bib-0066){ref-type="ref"}                                            Placebo              61                          43.7     12.7          62     90.2                       21.2                 20                                  19.9         12.2              48   21   26      15      19.4    6.7            
  Secukinumab 300 mg                                                                                                                    60                   60            46.6          14.2     77            91.0   23.1                       23                   21.0                                13.5                      50   25   26   13      18.9    6.4                    
  FEATURE[67](#jdv15277-bib-0067){ref-type="ref"}, [68](#jdv15277-bib-0068){ref-type="ref"}                                             Placebo              59                          46.5     14.1          66     88.4                       21.6                                                     20.2         14.2              49   44                   21.1    8.5            
  Secukinumab 300 mg                                                                                                                    59                   59            45.1          12.6     64            92.6   25.9                                            18.0                                11.9                      34   39   33   18      20.7    8.0                    
  ERASURE[33](#jdv15277-bib-0033){ref-type="ref"}                                                                                       Placebo              248                         45.4     12.6          69     89.7                       25.0                 27                                  17.3         12.4              44   29   30      16      21.4    9.1     12.0   
  Secukinumab 300 mg                                                                                                                    245                  238           44.9          13.5     69            88.8   24.0                       23                   17.4                                11.1                      52   29   33   19      22.5    9.2     13.9           
  UNCOVER‐3[38](#jdv15277-bib-0038){ref-type="ref"}, [69](#jdv15277-bib-0069){ref-type="ref"}                                           Placebo              193                         46.0     12.0          71     91.0                       21.0                                                     18.0         13.0         31   43   17   29      17      21.0    8.0     13.0   7.0
  Ixekizumab 80 mg Q2W→Q4W                                                                                                              385                  362           46.0          13.0     66            90.0   23.0                                            18.0                                12.0         39           44   15   28   17      21.0    8.0     12.0    7.0    
  X‐PLORE[70](#jdv15277-bib-0070){ref-type="ref"}                                                                                       Placebo              42                          46.5                   67     93.6                       22.6                 29                                  18.0         13.3         50   50   36   28      19      21.8    10.0           
  Adalimumab 40 mg Q2W                                                                                                                  43                   38            50.0                   70            91.6   19.9                       26                   19.3                                12.8         56           40   60   27   17      20.2    7.6                    
  Gordon 2006[42](#jdv15277-bib-0042){ref-type="ref"}                                                                                   Placebo              52                          43.0     20--70        65     94.0                       50--147              31                                  19.0         1--40                  0    28      7--75   16.0    5--40   12.2   8.1
  Adalimumab 40 mg Q2W                                                                                                                  46                   42            46.0          20--71   71            93.0   63--159                    33                   21.0                                1--58                          0    29   6--58   16.7    5--39   13.3    8.8    
  LIBERATE[44](#jdv15277-bib-0044){ref-type="ref"}                                                                                      Placebo              84                          43.4     14.9          70     89.5                       23.1                                                     16.6         12.1              83   0    27      16      19.4    6.8     11.4   6.3
  Apremilast 30 mg BID                                                                                                                  83                   74            46.0          13.6     59            88.5   19.8                                            19.7                                12.7                      80   0    27   16      19.3    7.0     13.6    6.7    
  Tyring 2006[47](#jdv15277-bib-0047){ref-type="ref"}                                                                                   Placebo              306                         45.6     12.1          70     91.0                                            33                                  19.7         11.4                   0    27      17      18.1    7.4     12.5   6.7
  Etanercept 50 mg BIW                                                                                                                  311                  304           45.8          12.8     65            92.6                              35                   20.1                                12.3                           0    27   18      18.3    7.6     12.1    6.7    
  Torii 2010[46](#jdv15277-bib-0046){ref-type="ref"}                                                                                    Placebo              19                          43.3     12.3          74     69.7                       8.9                  37                                  11.1         6.4          74   95        50      27      33.1    15.6    10.5   6.8
  Infliximab 5 mg/kg                                                                                                                    35                   32            46.9          13.0     63            68.5   13.4                       29                   14.2                                8.9          63           94        46   21      31.9    12.8    12.7    6.8    
  EXPRESS[45](#jdv15277-bib-0045){ref-type="ref"}, [71](#jdv15277-bib-0071){ref-type="ref"}                                             Placebo              77                          43.8     12.6          79     89.3                       18.7                 29                                  17.3         11.1         71   46   0    34      18      22.8    8.7     11.8   7.5
  Infliximab 5 mg/kg                                                                                                                    301                  281           42.6          11.7     69            85.9   20.1                       31                   19.1                                11.0         65           42   0    34   19      22.9    9.3     12.7    7.0    
  EXPRESS II[48](#jdv15277-bib-0048){ref-type="ref"}                                                                                    Placebo              208                         44.4     12.5          69     91.1                       22.6                 26                                                            50        13   28      18      19.8    7.7     13.4   7.3
  Infliximab 5 mg/kg                                                                                                                    314                  150           44.5          13.0     65            92.2   23.2                       28                                                                    55                14   29   16      20.4    7.5     13.1    7.0    

The analyses do not include placebo arms from AMAGINE‐2, AMAGINE‐3, CLEAR and FIXTURE trials.

BID, twice daily; BIW, twice weekly; BSA, body surface area; DLQI, dermatology life quality index; Ind, induction; Maint, maintenance; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis; PUVA, psoralen and ultraviolet A; Q2W, every 2 weeks; Q4W, every 4 weeks; SD, standard deviation; UVB, ultraviolet B; WBD, weight‐based dose.

John Wiley & Sons, Ltd

![Network diagram of Psoriasis Area and Severity Index (PASI) responses -- primary and secondary analyses.](JDV-33-355-g003){#jdv15277-fig-0003}

Risk of bias {#jdv15277-sec-0015}
------------

The risk of bias among the included studies was somewhat heterogeneous, but most were rated as being low risk of bias (Figure [S1](#jdv15277-sup-0001){ref-type="supplementary-material"}). Of the 17 included RCTs, four (24%) reported an adequate randomization method and 14 (82%) supplied sufficient information to assess whether allocation concealment was properly ensured. In four studies, the blinding of participants and personnel was insufficient as the long‐term extension was open label.[42](#jdv15277-bib-0042){ref-type="ref"}, [47](#jdv15277-bib-0047){ref-type="ref"}, [48](#jdv15277-bib-0048){ref-type="ref"} In all studies, the risk of attrition bias was low, as incomplete outcome data were sufficiently addressed. The risk of reporting bias was low in most of the studies. The risk of bias for each study is presented in Figure [S2](#jdv15277-sup-0001){ref-type="supplementary-material"}.

Efficacy {#jdv15277-sec-0016}
--------

### Analysis 1: NMA of 52‐week active therapy RCTs {#jdv15277-sec-0017}

The relative treatment effects for comparisons between brodalumab, ustekinumab (weight‐based dosing), secukinumab and etanercept (50 mg twice weekly) are presented in Table [2](#jdv15277-tbl-0002){ref-type="table"}. Results indicate that brodalumab is associated with significantly higher proportions of PASI 75, PASI 90 and PASI 100 responders compared to secukinumab, ustekinumab and etanercept. Secukinumab was also found to be more efficacious than ustekinumab, and both were found to outperform etanercept.

###### 

NMA of 52‐week active therapy RCTs (Analysis 1): results on PASI responses

  Intervention vs.   Comparator          Median risk ratio (95% credible interval)                        
  ------------------ ------------------- ------------------------------------------- -------------------- -------------------
  BRO                SEC                 1.10 (1.01--1.41)                           1.17 (1.03--1.61)    1.32 (1.06--2.02)
  UST                1.27 (1.05--1.94)   1.46 (1.1--2.41)                            1.90 (1.26--3.46)    
  ETN                1.65 (1.11--3.65)   2.11 (1.23--5.34)                           3.31 (1.58--10.00)   
  SEC                UST                 1.15 (1.03--1.48)                           1.23 (1.05--1.67)    1.4 (1.12--2.07)
  ETN                1.49 (1.10--2.66)   1.79 (1.19--3.49)                           2.48 (1.44--5.39)    
  UST                ETN                 1.28 (1.05--2.00)                           1.43 (1.09--2.42)    1.73 (1.18--3.29)

Results from fixed‐effect multinomial likelihood model with probit link and presented as risk ratios, with 95% credible intervals in parentheses below.

BRO, brodalumab 210 mg; ETN, etanercept 50 mg twice weekly; NMA, network meta‐analysis; PASI, Psoriasis Area and Severity Index; RCTs, randomized controlled trials; SEC, secukinumab 300 mg; UST, ustekinumab (45 mg if \<100 kg; 90 mg if \>100 kg).

John Wiley & Sons, Ltd

### Analysis 2: NMA of 52‐week RCTs using induction phase placebo control {#jdv15277-sec-0018}

Results of the analysis in which maintenance phase outcomes for active therapies were compared to induction phase outcomes for placebo showed all treatments to be significantly more efficacious than placebo. In terms of PASI responses, the most effective therapies in the network were brodalumab followed by ixekizumab and secukinumab, whereas apremilast showed the poorest efficacy of achieving any level of PASI response (Table [3](#jdv15277-tbl-0003){ref-type="table"} and Figure [S3](#jdv15277-sup-0001){ref-type="supplementary-material"}).

###### 

NMA of 52‐week RCTs using induction phase placebo control (Analysis 2): results on PASI responses

  Intervention vs.   Comparator            Median risk ratio (95% Credible Interval)                          
  ------------------ --------------------- ------------------------------------------- ---------------------- ---------------------
  BRO                SEC                   1.1 (1.01, 1.41)                            1.18 (1.03, 1.63)      1.32 (1.06, 2.02)
  IXE                1.06 (0.96, 1.46)     1.11 (0.93, 1.73)                           1.21 (0.89, 2.23)      
  UST                1.27 (1.05, 1.94)     1.49 (1.11, 2.48)                           1.91 (1.27, 3.48)      
  UST 45 mg          1.2 (1.02, 2.04)      1.37 (1.04, 2.72)                           1.68 (1.09, 4.06)      
  UST 90 mg          1.13 (1, 1.75)        1.24 (1, 2.21)                              1.43 (1, 3.1)          
  APR                3.22 (1.36, 16.4)     5.47 (1.75, 36.35)                          11.61 (2.72, 103.4)    
  ADA                1.31 (1.02, 2.89)     1.57 (1.04, 4.32)                           2.07 (1.08, 7.5)       
  ETN                1.63 (1.11, 3.54)     2.15 (1.25, 5.43)                           3.26 (1.57, 9.64)      
  INF                1.25 (1.02, 2.26)     1.45 (1.06, 3.11)                           1.84 (1.12, 4.84)      
  PBO                19.86 (3.5, 231)      53.14 (6.7, 775.6)                          201.7 (18.01, 3683)    
  SEC                IXE                   0.98 (0.82, 1.16)                           0.96 (0.74, 1.24)      0.93 (0.64, 1.37)
  UST                1.15 (1.03, 1.48)     1.25 (1.06, 1.71)                           1.42 (1.13, 2.09)      
  UST 45 mg          1.09 (0.96, 1.57)     1.15 (0.93, 1.87)                           1.26 (0.89, 2.39)      
  UST 90 mg          1.03 (0.89, 1.35)     1.05 (0.84, 1.54)                           1.09 (0.76, 1.84)      
  APR                2.91 (1.33, 12.4)     4.58 (1.67, 24.39)                          8.66 (2.42, 58.94)     
  ADA                1.19 (0.95, 2.26)     1.32 (0.91, 3.05)                           1.56 (0.86, 4.58)      
  ETN                1.48 (1.1, 2.59)      1.82 (1.2, 3.49)                            2.45 (1.44, 5.18)      
  INF                1.13 (0.97, 1.73)     1.23 (0.96, 2.13)                           1.39 (0.93, 2.84)      
  PBO                18.03 (3.44, 170)     44.82 (6.46, 504.3)                         151.3 (16.51, 2003)    
  IXE                UST                   1.17 (1.01, 1.68)                           1.29 (1.01, 2.08)      1.5 (1.02, 2.8)
  UST 45 mg          1.12 (0.96, 1.66)     1.2 (0.94, 2.04)                            1.35 (0.91, 2.72)      
  UST 90 mg          1.05 (0.9, 1.43)      1.09 (0.84, 1.68)                           1.16 (0.77, 2.11)      
  APR                2.98 (1.34, 13)       4.78 (1.7, 26.17)                           9.29 (2.52, 65.72)     
  ADA                1.22 (0.96, 2.38)     1.38 (0.94, 3.28)                           1.67 (0.9, 5.1)        
  ETN                1.5 (1.1, 2.85)       1.87 (1.21, 4.05)                           2.59 (1.44, 6.51)      
  INF                1.16 (0.99, 1.84)     1.28 (0.98, 2.33)                           1.48 (0.96, 3.25)      
  PBO                18.51 (3.46, 177.2)   46.92 (6.56, 534.5)                         162.7 (17.11, 2210)    
  UST                UST 45 mg             0.97 (0.74, 1.25)                           0.94 (0.65, 1.37)      0.91 (0.54, 1.56)
  UST 90 mg          0.91 (0.67, 1.11)     0.86 (0.57, 1.16)                           0.78 (0.45, 1.25)      
  APR                2.5 (1.27, 9.27)      3.62 (1.5, 16.57)                           6 (1.94, 35.29)        
  ADA                1.04 (0.75, 1.77)     1.07 (0.66, 2.19)                           1.11 (0.54, 2.91)      
  ETN                1.27 (1.05, 1.93)     1.43 (1.09, 2.37)                           1.69 (1.17, 3.12)      
  INF                1 (0.77, 1.36)        0.99 (0.69, 1.54)                           0.99 (0.58, 1.82)      
  PBO                15.54 (3.32, 122.8)   35.42 (5.96, 326.1)                         104.7 (13.98, 1133)    
  UST 45 mg          UST 90 mg             0.95 (0.79, 1.02)                           0.91 (0.72, 1.03)      0.87 (0.63, 1.04)
  APR                2.61 (1.3, 9.76)      3.86 (1.56, 17.79)                          6.63 (2.1, 39.03)      
  ADA                1.08 (0.79, 1.86)     1.13 (0.7, 2.35)                            1.22 (0.59, 3.23)      
  ETN                1.31 (1.05, 2.16)     1.51 (1.09, 2.8)                            1.85 (1.16, 3.97)      
  INF                1.03 (0.8, 1.44)      1.06 (0.72, 1.67)                           1.09 (0.62, 2.05)      
  PBO                16.25 (3.38, 127)     37.97 (6.18, 344)                           116.4 (15.09, 1220)    
  UST 90 mg          APR                   2.78 (1.32, 11.16)                          4.28 (1.63, 21.28)     7.78 (2.3, 49.65)
  ADA                1.14 (0.88, 2.08)     1.24 (0.81, 2.74)                           1.41 (0.73, 3.98)      
  ETN                1.4 (1.08, 2.46)      1.67 (1.15, 3.33)                           2.17 (1.3, 5.02)       
  INF                1.09 (0.89, 1.61)     1.15 (0.84, 1.94)                           1.26 (0.77, 2.53)      
  PBO                17.33 (3.43, 149.5)   42.07 (6.37, 426.3)                         136.7 (16.04, 1619)    
  APR                ADA                   0.43 (0.12, 0.83)                           0.31 (0.07, 0.73)      0.19 (0.03, 0.62)
  ETN                0.52 (0.18, 0.88)     0.4 (0.12, 0.82)                            0.29 (0.07, 0.73)      
  INF                0.4 (0.11, 0.79)      0.28 (0.06, 0.66)                           0.17 (0.03, 0.51)      
  PBO                5.83 (2.29, 22.01)    9.09 (3.11, 39.46)                          16.05 (4.62, 82.94)    
  ADA                ETN                   1.18 (0.82, 2.04)                           1.3 (0.76, 2.63)       1.48 (0.69, 3.76)
  INF                0.96 (0.57, 1.39)     0.93 (0.46, 1.6)                            0.9 (0.34, 1.98)       
  PBO                14.51 (3.29, 107.6)   31.98 (5.81, 283.5)                         90.38 (13.29, 976.8)   
  ETN                INF                   0.8 (0.49, 0.99)                            0.71 (0.39, 0.98)      0.6 (0.28, 0.96)
  PBO                12.14 (3.13, 68.57)   24.49 (5.3, 154.4)                          61.07 (11.2, 428.2)    
  INF                PBO                   15.57 (3.35, 117.1)                         35.53 (6.05, 309.4)    105.3 (14.43, 1053)

Results from fixed‐effect multinomial likelihood model with probit link.

ADA, adalimumab 40 mg Q2W; APR, apremilast 30 mg BID; BID, twice daily; BIW, twice weekly; BRO, brodalumab 210 mg; ETN, etanercept 50 mg BIW; INF, infliximab 5 mg/kg; IXE, ixekizumab 80 mg Q2W→Q4W; NMA, network meta‐analysis; PASI, Psoriasis Area and Severity Index; PBO, placebo; Q2W, every 2 weeks; Q4W, every 4 weeks; RCTs, randomized controlled trials; SEC, secukinumab 300 mg; UST, ustekinumab (45 mg if \<100 kg; 90 mg if \>100 kg).
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Figure [4](#jdv15277-fig-0004){ref-type="fig"} presents the cumulative ranking curves for each treatment along with an estimate of the SUCRA line. A SUCRA would be 100% when a treatment is certain to be the best and 0% when it is certain to be the worst. Brodalumab was ranked the most efficacious therapy in 79% of Bayesian iterations, giving it the highest SUCRA value of 97%. Ixekizumab and secukinumab had the next highest SUCRA values, at 83% and 77%, respectively. Of active therapies, etanercept and apremilast had the lowest SUCRA values, at just 22% and 10%, respectively.

![Cumulative ranking probability plots and surface under the cumulative ranking (SUCRA) for each treatment included in network meta‐analysis (NMA) of 52‐week randomized controlled trials (RCTs) using induction phase placebo control (Analysis 2). On the horizontal axis is the possible rank of each treatment according to the magnitude of its treatment effect across all measures of Psoriasis Area and Severity Index (PASI) response (from the best rank \[1\] to worst \[11\]). On the vertical axis is the cumulative probability for each treatment to be the best option, among the best two options, among the best three options and so on. If a treatment always ranks first, then the SUCRA = 100%; if a treatment always ranks last, then the SUCRA = 0%. WBD, weight‐based dose.](JDV-33-355-g004){#jdv15277-fig-0004}

Results from the sensitivity analysis including only studies with at least 5% of patients reporting prior biologic exposure were consistent with the analysis including all studies regardless of prior biologic exposure (Table [S3](#jdv15277-sup-0001){ref-type="supplementary-material"}). With the exception of apremilast, for which there were no data in this sensitivity analysis, the relative rank and statistical significance of treatments effects between treatments were unchanged.

Discussion {#jdv15277-sec-0019}
==========

We performed a comprehensive systematic review and NMA summarizing the long‐term RCT evidence available for the efficacy of systemic biologic and non‐biologic drugs in the treatment of patients with moderate‐to‐severe psoriasis. This is the first NMA to synthesize maintenance phase outcomes reported at or around 1 year of follow‐up.

The synthesis of four RCTs reporting PASI outcomes at week 52 for brodalumab, ustekinumab, secukinumab and etanercept showed brodalumab to be associated with the highest likelihood of response. Based on these results, patients treated with brodalumab are 30% more likely to experience a complete clearance of psoriasis (PASI 100) at 1 year than patients treated with secukinumab, almost twice as likely as those treated with a weight‐based dose of ustekinumab and more than three times as likely as patients treated with a 50 mg twice weekly dose of etanercept.

We supplemented this 'purer' network with the inclusion of placebo‐controlled RCTs reporting maintenance phase outcomes for other licensed therapies, including adalimumab, apremilast, infliximab and ixekizumab. The newest generation biologic therapies -- brodalumab, ixekizumab and secukinumab -- were the best performing treatments, followed by ustekinumab, infliximab and adalimumab. Etanercept and apremilast had the lowest expected long‐term efficacy.

These findings are generally consistent with published NMAs on the induction phase efficacy of biologics for psoriasis and with a published meta‐analysis of 24‐week outcomes. Nast *et al*.[7](#jdv15277-bib-0007){ref-type="ref"} ranked drugs based on PASI 75 responses at 24 weeks, with the best results reported for infliximab, secukinumab and ustekinumab followed by adalimumab, etanercept and apremilast.

Patient registries, such as BADBIR in the United Kingdom and DERMBIO in Denmark, are another valuable source of long‐term data on the efficacy of biologic therapies for psoriasis. Several studies reporting analyses of drug survival from registry or other observational data sets have been published, and they showed ustekinumab to have similar[49](#jdv15277-bib-0049){ref-type="ref"} or longer drug survival compared to anti‐TNF agents.[50](#jdv15277-bib-0050){ref-type="ref"}, [51](#jdv15277-bib-0051){ref-type="ref"}, [52](#jdv15277-bib-0052){ref-type="ref"}, [53](#jdv15277-bib-0053){ref-type="ref"}, [54](#jdv15277-bib-0054){ref-type="ref"}, [55](#jdv15277-bib-0055){ref-type="ref"}, [56](#jdv15277-bib-0056){ref-type="ref"}, [57](#jdv15277-bib-0057){ref-type="ref"}, [58](#jdv15277-bib-0058){ref-type="ref"}, [59](#jdv15277-bib-0059){ref-type="ref"} It will be some time before published data are available for the newest biologics -- brodalumab, ixekizumab and secukinumab -- yet the RCT evidence and this analysis suggest that they will outperform older biologics in the long‐term.

Limitations {#jdv15277-sec-0020}
-----------

A number of challenges arise when attempting to quantitatively summarize the results of long‐term studies in psoriasis. They vary in study design, in their method of analysis and in their handling of missing data. Wherever possible, we used data from the intention‐to‐treat analysis population and the more conservative non‐responder imputation method. We included outcomes for patients receiving the licensed regimen of the intervention throughout each study, thus excluding patients who had crossed over following induction.

In the majority of long‐term RCTs, the placebo groups were discontinued after induction. As comparative data are fundamental to meta‐analysis (both pairwise and network), we imputed these missing long‐term outcomes for placebo by carrying forward responses measured at the end of induction (10--16 weeks). We are aware that this approach is associated with uncertainties; however, the stability of placebo responses recorded between the end of induction up to week 24 in four RCTs[45](#jdv15277-bib-0045){ref-type="ref"}, [60](#jdv15277-bib-0060){ref-type="ref"}, [61](#jdv15277-bib-0061){ref-type="ref"}, [62](#jdv15277-bib-0062){ref-type="ref"} lends some support to our assumption. In their meta‐analysis of 24‐week outcomes, Nast *et al*.[7](#jdv15277-bib-0007){ref-type="ref"} dealt with this problem by calculating a mean placebo response from three studies that reported placebo data up to week 24 and used it as a model for trials without a long‐term placebo control, a method of adjustment that breaks randomization. More long‐term direct evidence is required to increase the quantity and validity of possible comparisons, thus active‐controlled RCTs make the most sense ethically and methodologically.

The number of therapies coming to market for the treatment of moderate‐to‐severe psoriasis is evolving rapidly, and already licensed therapies are still being evaluated in active‐comparator trials. Since the search was performed for this systematic review, three treatments have received marketing authorization for psoriasis in either the United States, Europe or both: guselkumab, certolizumab pegol and tildrakizumab. Due to their very nature, systematic reviews are challenged by the rate of publications in this disease area, and further updates will inevitably be required as and when long‐term RCT data mature for these newer therapies.

Conclusions {#jdv15277-sec-0021}
===========

This NMA of long‐term RCT evidence demonstrates that high levels of sustained efficacy can be expected from IL‐17A inhibitor secukinumab, and IL‐17RA receptor blocker brodalumab, with brodalumab achieving the highest rates of PASI response up to and including PASI 100. Our secondary analysis indirectly compared the IL‐17 blocking agents with older biologics and apremilast, and although there was more uncertainty, it supported the conclusion that IL‐17A inhibitors and the IL‐17RA receptor blocker are the most efficacious medicines in the currently available treatment arsenal to treat moderate‐to‐severe psoriasis. Long‐term active‐comparator trials are needed to validate these conclusions.
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**Figure S1.** Risk of bias graph: review author\'s judgements about each risk of bias item presented as percentages across all included studies.

**Figure S2.** Risk of bias summary for individual studies.

**Figure S3.** Network meta‐analysis (NMA) of 52‐week randomized controlled trials (RCTs) using induction phase placebo control (Analysis 2): results as probabilities of achieving each level of Psoriasis Area and Severity Index (PASI) response.

**Table S1.** Embase search terms.

**Table S2.** Study‐level response data.

**Table S3.** Sensitivity analysis of network meta‐analysis (NMA) of 52‐week randomized controlled trials (RCTs) using induction phase placebo control (Analysis 2) excluding studies with \<5% of patients reporting prior biologic exposure: results on Psoriasis Area and Severity Index (PASI) responses.
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